Flaharty Asset Management LLC Acquires Shares of 5,343 Pfizer Inc. $PFE

Flaharty Asset Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,343 shares of the biopharmaceutical company’s stock, valued at approximately $135,000.

Other hedge funds have also recently made changes to their positions in the company. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter worth about $27,000. North Capital Inc. bought a new position in shares of Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the 4th quarter worth about $30,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. HSBC cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Berenberg Bank cut their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Finally, Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Stock Up 0.8%

NYSE:PFE opened at $24.74 on Wednesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market capitalization of $140.66 billion, a P/E ratio of 13.16, a P/E/G ratio of 0.87 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company’s 50-day simple moving average is $24.85 and its 200-day simple moving average is $24.33.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period last year, the business earned $0.60 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.